The acquisition of LDI Integrated Pharmacy Services marks Diplomat’s second PBM acquisition this month, having acquired National Pharmaceutical Services on Nov. 6.
Specialty Pharmacy News
This acquisition will enhance McKesson’s commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including comprehensive patient support, or “hub,” services.
Diplomat Pharmacy has a new member of its executive leadership team who brings with her more than a quarter-century of industry experience.
Yescarta, from Gilead’s recently acquired company Kite, was approved to treat relapsed or refractory large B-cell lymphoma following two or more lines of systemic therapy.
As specialty growth looks set to plateau, the drug class continues to see its share of per-capita spending increase, with a decline in spending on traditional medicines creating space for more specialty share.
According to the World Health Organization, roughly one-third of patients diagnosed with plaque psoriasis is younger than 20 years of age, and adolescents in particular have limited treatment options.
The drug was approved to treat certain cases of advanced or metastatic breast cancer, either alone or in combination with Faslodex.
The newly re-launched product is Health Canada compliant and has been available for purchase online since Sept. 29.